Seeking Alpha
 

iShares U.S. Healthcare Providers ETF (IHF)

- NYSEARCA
  • Oct. 2, 2013, 4:07 AM
    • Millions of people visited the Web sites of health-insurance exchanges yesterday on their first day of operations, although, as expected, many of the sites were beset by technical glitches.
    • It's unclear how much of the traffic translated into sales - Connecticut's site received 28,000 hits as of 4 pm but only 167 people had applied to buy insurance.
    • The exchanges have been created as a key part of Obamacare.
    • Health insurers that are selling plans on exchanges include UnitedHealth (UNH), Aetna (AET), WellPoint (WLP), Health Net (HNT) and Humana (HUM). Molina Healthcare (MOH) is also playing a role.
    • ETFs: XLV, XHE, VHT, FXH, IHF, IHI, IYH, PTH, RYH, PSCH, RXL, RXD, XHS.
    | Oct. 2, 2013, 4:07 AM | 2 Comments
  • Sep. 29, 2013, 1:50 AM
    • While the health exchanges that are a key part of Obamacare are due to open for business on Tuesday, some states won't be able to offer full functionality at first because of IT problems.
    • The states include New York, Oregon and Colorado, as well as the District of Columbia.
    • In addition, the Obamacare Spanish-language Internet site won't be ready, while small businesses and their staff won't be able to sign up for weeks.
    • The contractors involved include IBM (IBM) and Infosys (INFY)
    • ETFs: XLV, XHE, VHT, FXH, IHF, IHI, IYH, PTH, RYH, PSCH, RXL, RXD, XHS.
    | Sep. 29, 2013, 1:50 AM | 17 Comments
  • Sep. 25, 2013, 3:08 AM
    • The average cost of a mid-tier health insurance plan under Obamacare is $328 a month, price data from the government showed yesterday, just a week before enrollment in the healthcare overhaul is due to begin on October 1.
    • As you'd expect, prices were cheaper in the states with more competition.
    • The Obama administration hopes to sign up 7M consumers in the first year, with 2.7M young and healthy Americans set to pay for those who are older and sicker. The average premium for a 27-year-old nonsmoker will range from $163-$240 a month.
    • Health insurers that intend to sell plans on some exchanges include UnitedHealth (UNH), Aetna (AET), WellPoint (WLP) and Humana (HUM). Molina Healthcare (MOH) is also set to play a role.
    • ETFs: XLV, XHE, VHT, FXH, IHF, IHI, IYH, PTH, RYH, PSCH, RXL, RXD, XHS.
    | Sep. 25, 2013, 3:08 AM | 8 Comments
  • Sep. 12, 2013, 10:07 AM
    • U.S. bio-pharmaceutical companies are developing 271 vaccines to prevent and even treat numerous conditions, a report from the Pharmaceutical Research & Manufacturers of America says.
    • The conditions targeted include infectious diseases and various forms of cancer and neurological disorders.
    • In the U.S., 10 infectious diseases have been at least 90% eradicated because of vaccines.
    • ETFs: XLV, XHE, VHT, FXH, IHF, IHI, IYH, PTH, RYH, PSCH, RXL, RXD, XHS, XPH, IHE, PJP, PPH, DRGS
    | Sep. 12, 2013, 10:07 AM | Comment!
  • May 31, 2013, 2:49 PM
    Stocks turn lower (DIA -0.5%) 90 minutes ahead of the bell as Treasury prices tumble anew (TLT -1.2%), the 10-year yield gaining another 9 bps to 2.20%. The levered Treasury short ETF (TBT +2.5%) hits a 52-week high. Again hardest hit are the previously hot defensive sectors whose yields no longer stand so tall over Treasurys. Health care (XLV -1.1%), Consumer staples (XLP -1.1%). Utilities (XLU +0.1%) however, get a respite from an ugly month.
    | May 31, 2013, 2:49 PM | 6 Comments
  • May 17, 2013, 8:13 AM
    Thomas Lee lifts his year-end S&P 500 (SPY) forecast to 1,715 from 1,580 as the bull has already outrun his expectations. His team sees clues economic performance is picking up, including the outperformance of semiconductors (XSD) vs. transports (IYT), and the steepening of the 10 year/30 year Treasury curve. Risk/reward is particularly appealing in tech (XLK), healthcare (XLV), and financials (XLF).
    | May 17, 2013, 8:13 AM | Comment!
  • May 16, 2013, 11:42 AM
    The Dow and S&P 500 are flat, but the Nasdaq gains 0.4% late morning behind a 12.5% jump in Cisco post-earnings and Apple bouncing from the last 2 days' drubbing, up 1.5%. Dragging the Dow is a 2.1% decline in Wal-Mart post-earnings. The notably weak sector today is the year's hottest, healthcare (XLV -0.8%).
    | May 16, 2013, 11:42 AM | 1 Comment
  • May 6, 2013, 7:27 AM
    The S&P 500 (SPY) is fairly valued, says Goldman, but opportunity lies in cyclicals (XLY, XLE, XLI, XLB) which are more undervalued vs. defensives (XLU, XLP, XLV, XTL) than at any time in the last 15 years. "Given the 4 P/E multiple point head start, even a slight valuation normalization should translate into outperformance of cyclicals over defensives during the next 12 months."
    | May 6, 2013, 7:27 AM | 1 Comment
  • Apr. 26, 2013, 8:34 AM
    The beginning of a bigger move? Two of the year's three strongest performing sectors - healthcare (XLV) and consumer staples (XLP) - are down on the week as the three weakest sectors - energy (XLE), materials (XLB), and tech (XLK) - post gains of 3%-4.5%.
    | Apr. 26, 2013, 8:34 AM | 2 Comments
  • Apr. 2, 2013, 1:22 PM
    Already the best sector YTD, Healthcare widens its lead even further thanks to hikes in Medicaid Advantage rates. The XLV's 17.1% gain is more than 200 bps greater than 2nd place Consumer Staples (XLP), and about 700 bps better than SPY. Getting a relative drubbing are Materials (XLB) and Tech (XLK) - each up less than 4%.
    | Apr. 2, 2013, 1:22 PM | Comment!
  • Mar. 22, 2013, 10:39 AM
    The health care sector (IYH, XLV) is outperforming the S&P 500 (SPY) through the year's first 11 weeks for the first time in 15 years as companies cut costs and investors bet whatever emanates from D.C. will be good for all involved. "Most of the big drug companies have experienced patent cliffs and are now repositioning themselves for growth," says one fund manager. 
    | Mar. 22, 2013, 10:39 AM | 2 Comments
  • Jan. 8, 2013, 6:04 AM
    Healthcare spending rose at a record low pace of 3.9% to $2.7T in 2011 as patients continued to cut back on medical services amid the economic slump. The growth was the same as in 2010 and 2009, and well below the 8% prior to the financial crisis. However, there are signs the rise in spending could be speeding up again, with expenditure on drugs increasing by 2.9% in 2011 vs 0.4% in 2010, and on doctors' visits by 4.3%.
    | Jan. 8, 2013, 6:04 AM | Comment!
  • Jan. 2, 2013, 9:44 AM
    The Street's Adam Feuerstein makes 13 biotech stock predictions for 2013, with his number one being that the U.S. launch of Arena Pharmaceuticals' (ARNA) and Eisai's weight-loss pill Belviq "will be a major disappointment." Feuerstein also reckons that Belviq will fail to receive European approval.
    | Jan. 2, 2013, 9:44 AM | 17 Comments
  • Jan. 1, 2013, 6:49 AM
    The number of drugs that the FDA authorized in 2012 rose to 39 from 30 last year and 21 in 2010, with the figure the highest since 53 in 1996. It also includes 10 medicines with fast-track status. The increase in approvals should help offset the patent cliff, which cost major U.S. and European drug companies $31B in revenues last year. (graph of approvals)
    | Jan. 1, 2013, 6:49 AM | Comment!
  • Dec. 9, 2012, 2:27 AM
    The Supreme Court will review a "pay for delay" case in which Solvay, now owned by Abbott Labs (ABT), paid three generic drug companies to up to $40M a year, including Watson (WPI), to postpone making copycat versions of Solvay's Androgel testosterone treatment. The case has industry wide ramifications, with the FTC saying the practice costs customers $3.5B a year. (previous)
    | Dec. 9, 2012, 2:27 AM | 1 Comment
  • Nov. 19, 2012, 10:01 AM
    President Obama's re-election did not, as some believe, bring an end to the battle over Obamacare, write James Capretta and Yuval Levin in the WSJ. That's because the Administration is reliant on states for two key elements of the the reform: health-insurance exchanges and expanding Medicaid. Some GOP governors have already said "they won't do the federal government's bidding." Capretta and Levin explain why they agree.
    | Nov. 19, 2012, 10:01 AM | Comment!
Visit Seeking Alpha's
IHF vs. ETF Alternatives
IHF Description
The iShares Dow Jones U.S. Healthcare Providers Index Fund seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the Dow Jones U.S. Select Health Care Providers Index.
See more details on sponsor's website
Sector: Healthcare
Country: United States
ETF Hub
Find the right ETFs for your portfolio: Visit Seeking Alpha's ETF Hub